← Back to guidelines
Pediatrics1 paper

Familial renal iminoglycinuria

Last edited: 4/16/2026

Overview

Familial renal iminoglycinuria is an autosomal recessive condition characterized by massive selective hyperiminoglycinuria of proline, hydroxyproline, and glycine, detected in early infancy through urine screening. It is benign and does not affect plasma concentrations of these amino acids or glomerular filtration rate 1.

Diagnosis

  • Key Diagnostic Criteria: Massive urinary excretion of proline, hydroxyproline, and glycine detected in the second week of life.
  • Recommended Tests: Urine screening for amino acid levels, plasma amino acid concentrations, and assessment of creatinine clearance.
  • Genetic Testing: Identification of at least two different mutant alleles through family studies 1.
  • Management

  • No Specific Treatment Required: The condition is benign and does not necessitate specific medical intervention 1.
  • Monitoring: Regular follow-up to ensure normal maturation of tubular reabsorption and absence of complications 1.
  • Special Populations

  • Pediatrics: Condition identified in infants; no specific pediatric management beyond monitoring is indicated 1.
  • Comorbidities: No evidence of comorbidities affecting management in the provided abstracts 1.
  • Key Recommendations

  • Perform urine screening for proline, hydroxyproline, and glycine in early infancy to diagnose familial renal iminoglycinuria (Evidence: Expert opinion) 1.
  • Confirm diagnosis with plasma amino acid levels and genetic testing to identify specific mutant alleles (Evidence: Expert opinion) 1.
  • Monitor affected infants for normal renal function and maturation of tubular reabsorption without specific therapeutic intervention (Evidence: Expert opinion) 1.
  • References

    1 Lasley L, Scriver CR. Ontogeny of amino acid reabsorption in human kidney. Evidence from the homozygous infant with familial renal iminoglycinuria for multiple proline and glycine systems. Pediatric research 1979. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG